2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

2:30PM-4:00PM: Abstract Number: 905

Serum Interleukin-6 Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

3S090 ACR Abstract: Vasculitis–ANCA-Assocd (904–909)

2:30PM-4:00PM: Abstract Number: 877

Serum Krebs Von Den Lungen-6 Is a Useful Biomarker for Assessing Activity of Myositis-Associated Interstitial Lung Disease

3S084 ACR Abstract: Muscle Biology, Myositis & Myopathies I: Biomarkers (875–879)

2:30PM-4:00PM: Abstract Number: 865

Structural and Microstructural Intraarticular Bone Changes at the Metacarpal Heads in Patients with Psoriatic Arthritis Compared to Controls: A HR-pQCT Study

3S082 ACR Abstract: Imaging of Rheumatic Diseases I: MRI & CT (863–868)

2:30PM-4:00PM: Abstract Number: 909

Temporal Trends of ANCA-Associated Vasculitis Comorbidities: Results from a National, Longitudinal, Matched-Cohort Study

3S090 ACR Abstract: Vasculitis–ANCA-Assocd (904–909)

2:30PM-4:00PM: Abstract Number: 915

The Association between Structural and Symptomatic Progression in Knee Osteoarthritis

3S093 ACR/ARHP Abstract: Epidemiology & Pub Health (910–915)

2:30PM-4:00PM: Abstract Number: 840

The CCL21/CCR7 Axis Drives Vascular, Inflammatory and Destructive Remodeling in Rheumatoid Arthritis

3S080 ACR Abstract: Cytokines & Cell Trafficking (840–845)

2:30PM-4:00PM: Abstract Number: 864

The Diagnostic Utility of the Relation between MRI Bone Marrow Edema and Other Types of MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis

3S082 ACR Abstract: Imaging of Rheumatic Diseases I: MRI & CT (863–868)

2:30PM-4:00PM: Abstract Number: 841

TNFR2 Inactivation Reduces Psoriatic Inflammation in Mice Via Down-Regulating Dendritic Cell Expansion and Inhibiting IL-23/IL-17 Pathways

3S080 ACR Abstract: Cytokines & Cell Trafficking (840–845)

2:30PM-4:00PM: Abstract Number: 889

Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

3S087 ACR Abstract: RA–Treatments I: JAK Inhibitors (886–891)

2:30PM-4:00PM: Abstract Number: 859

Using Online Simulation of Pediatric Musculoskeletal Cases to Evaluate How Knowledge of Costs Affects Diagnostic Workup

3S081 ACR Abstract: Education (857–862)

4:30PM-6:00PM: Abstract Number: 924

10X Genomics-Based Single-Cell RNA-Seq and Low Input RNA-Seq Identify a Transcriptional Landscape Supporting Interferon in the Pathogenesis of Autoimmune-Associated Congenital Heart Block

3S106 ACR Abstract: Pediatric Rheumatology–Basic Science (922–927)

4:30PM-6:00PM: Abstract Number: 919

A Machine Learning Classifier for Assigning Individual Patients with Systemic Sclerosis to Intrinsic Molecular Subsets

3S103 ACR Abstract: Genetics, Genomics & Proteomics: Precision Medicine (916–921)

4:30PM-6:00PM: Abstract Number: 954

A New Way to Think about Composite Magnetic Resonance Imaging Scores to Measure Osteoarthritis Severity and Progression

3S105 ACR Abstract: Osteoarthritis–Clinical (952–957)

4:30PM-6:00PM: Abstract Number: 918

A Novel Familial RELA Truncation Is Associated with Behçet’s-like Mucocutaneous Ulceration Syndrome

3S103 ACR Abstract: Genetics, Genomics & Proteomics: Precision Medicine (916–921)

4:30PM-6:00PM: Abstract Number: 971

A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept or Placebo on Standard of Care in Patients with Active Class III or IV Lupus Nephritis

3S110 ACR Abstract: SLE–Clinical I: Clinical Trials (970–975)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].